Zepbound®
Tirzepatide · GLP-1 / GIP Injection
The US-licensed sibling of Mounjaro — weekly dual-action weight-loss injection.
Zepbound® is Eli Lilly’s weight-management brand of tirzepatide — the same dual GLP-1 / GIP molecule as Mounjaro®. Licensed in the US specifically for chronic weight management, it is one of the most effective weight-loss medications ever licensed in clinical trials. In the UK, tirzepatide is also available under the Mounjaro brand; Zepbound is offered for patients who specifically request the Lilly US formulation.
- Active ingredient
- Tirzepatide
- Format
- Single-dose pre-filled pen
- Frequency
- Once weekly
- Prescription
- Required
Benefits
Why patients choose Zepbound®.
Industry-leading weight loss
Average 20%+ body-weight reduction at the 15 mg dose in SURMOUNT trials.
Weekly injection
Single weekly dose — easy to remember, easy to fit into any lifestyle.
Powerful appetite control
Dual hormone action helps calm cravings and reduce portion size naturally.
Clinician-reviewed
Every order is approved by a UK-qualified prescriber before dispatch.
How it works
A simple, evidence-based approach.
- 1
One self-administered subcutaneous injection every 7 days.
- 2
Dual GLP-1 + GIP receptor activation reduces appetite and improves insulin response.
- 3
Dose is titrated every 4 weeks from 2.5 mg up to 15 mg based on response and tolerance.
- 4
Pairs best with a calorie-reduced eating pattern and regular physical activity.
Choose your dose
Prescription-only medicine. Every order is reviewed by a UK-registered prescriber before dispatch.
Questions
Zepbound® FAQs
Everything you need to know before starting your course.
Alternatives
